Axa S.A. Bluebird Bio, Inc. Transaction History

Axa S.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $37,107 - $66,899	-13,300 Reduced 54.29%	11,200 $36,000
Q1 2023 May 15, 2023	SELL	$3.14 - $8.22 $47,100 - $123,300	-15,000 Reduced 37.97%	24,500 $77,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $227,914 - $335,355	39,500 New	39,500 $273,000
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $3.44 Million - $7.03 Million	-207,564 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $1.17 Million - $1.61 Million	42,525 Added 25.77%	207,564 $8.98 Million
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $1.08 Million - $1.37 Million	31,388 Added 23.49%	165,039 $8.9 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $3.62 Million - $6.14 Million	133,651 New	133,651 $8.16 Million
Q3 2018 Nov 08, 2018	SELL	$88.86 - $117.49 $1.84 Million - $2.43 Million	-20,700 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$99.64 - $127.59 $478,272 - $612,432	-4,800 Reduced 18.82%	20,700 $3.25 Million
Q1 2018 May 14, 2018	BUY	$105.8 - $150.94 $63,480 - $90,564	600 Added 2.41%	25,500 $4.35 Million
Q4 2017 Feb 13, 2018	BUY	$81.25 - $130.7 $1.13 Million - $1.82 Million	13,900 Added 126.36%	24,900 $4.44 Million
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $635,140 - $1.01 Million	11,000	11,000 $1.51 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.